Trial Profile
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Domvanalimab (Primary) ; Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC-8
- Sponsors AstraZeneca; AstraZeneca AB
- 02 Feb 2024 Planned End Date changed from 28 Sep 2029 to 30 Aug 2030.
- 02 Feb 2024 Planned primary completion date changed from 2 Jun 2027 to 27 Jun 2028.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.